πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 7 of 173

  1. US 12220453

    Compositions and treatments for Haemophilus influenzae

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12221463

    Method of promoting wound healing by inhibiting CCR3

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12220421

    Inhibitors of C. difficile spore germination

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12221622

    Modified pluripotent cells

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12221612

    Plants having increased oil quality

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12221629

    Methods for producing fibroadipogenic progenitor cells

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12222355

    Therapeutic antibodies against ROR-1 protein and methods for use of same

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12220595

    Stem cell rich plasma compositions and uses thereof for treating aging subjects

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12215162

    BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12213977

    Methods and compositions for treating melanoma

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12214014

    Methods for scar reduction by converting scar fibroblasts into adipocytes with hair follicle-derived signals

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12215060

    Performance of technical ceramics

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12215343

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12213996

    Methods of treating optic nerve diseases using neural progenitor cell growth factors

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12209240

    Antisense antibacterial compounds and methods

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12208227

    Precision bio-chemotronic system

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12209255

    Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12209140

    Therapeutics for the treatment of glaucoma

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12209120

    Activatable anti-VEGF scFv

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12208069

    Antibiofilm formulations

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12209119

    Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12202798

    Antimicrobial compounds, compositions, and articles of manufacture for selectively inhibiting pathogenic microbes

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12202877

    T cell receptors with mage-B2 specificity and uses thereof

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12202880

    HLA engineering methods and compositions for treatment of autoimmunity

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12202841

    Therapeutic agents for enhancing epithelial and/or endothelial barrier function

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12201700

    Micro- and nano-device for cartilage injury detection and treatment

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12202895

    LILRB4 antibodies and uses thereof

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12201453

    Microneedle fabrication and device implantation

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12201598

    Immunoregulatory microparticles for modulating inflammatory arthritides

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12203143

    Methods and kits to identify Klebsiella strains

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12201684

    Compositions for stimulation of mammalian innate immune resistance to pathogens

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12201655

    Antimicrobial therapy

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12195620

    Controlled entrapment and release of molecular cargo

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12195540

    Antibodies that bind integrin Ξ±vΞ²8 and uses thereof

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12194082

    Compositions and methods for treatment of homocystinuria

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12194059

    Compositions comprising citrate and applications thereof

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12194091

    Antibodies that bind human C6 and uses thereof

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12195804

    Treatment of squamous cell carcinoma

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12195766

    Tumor-selective E1a and E1b mutants

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12186369

    Gene therapy strategy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12187694

    SLC26A3 inhibitors and use thereof

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12188069

    Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12186368

    Compositions and methods for treatment of protease mediated disease

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12187777

    Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12188949

    Noninvasive method to quantify kidney function and functional decline

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12187780

    Car t-cells comprising inactivated CBL and CBL-B genes

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12188926

    Stimuli responsive microsphere composites

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12187848

    Compositions and methods for cellular delivery

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.